ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

All Content

The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.

As part of our coverage of the ASH Annual Meeting, we are discussing novel agents and strategies for relapsed/refractory Hodgkin lymphoma.

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

Gentle reader, the hour is late. As the poet said, almost all of the grains of sand allotted to 2016 have sifted down onto the pyramid of memory. Before this year’s hourglass empties, though, let’s take a moment to reflect on some of the phenomena we observed during the past months in this esoteric branch of medicine.

In patients with HER2-positive breast cancer undergoing trastuzumab therapy, the use of an ACE inhibitor or beta-blocker could protect against cardiac toxicity.

A 60-year-old man with a history of chronic obstructive pulmonary disease presents with pain in the left side of his abdomen. What is your diagnosis?

A 47-year-old woman presents with a mass in her right calf, and a biopsy is performed. What is your diagnosis?

Researchers have identified characteristics associated with improved outcomes when treating BRAF-mutated advanced melanoma with the combination of dabrafenib and trametinib.

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

In this slide show we highlight some of the top news on lung cancer in 2016, including an immunotherapy approval from the FDA, and studies on depression in lung cancer patients, serious side effects to watch for when using immunotherapies, and more.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.